What Лантус Treats: Main Uses and Benefits

This medication is commonly used to help with the management of blood glucose.

Лантус is primarily used for the long-term management of Diabetes Mellitus Type 1 and Type 2, applied in addressing chronic, persistent high blood sugar (hyperglycemia). It may serve as a component of background insulin therapy, which is relevant in conditions where the body's natural insulin supply is diminished or insufficient. This medication is applied in addressing the symptom cluster of glucose variability, focusing on the periods between meals and the entire overnight fasting phase.

The profile of this insulin generally provides steady support and helps smooth out unpredictable sugar fluctuations. Its role contributes to predictable stability that assists with maintaining functional stability when symptoms are more noticeable. This effect helps improve day-to-day comfort, supports the management of fasting plasma glucose (FPG) levels toward a target range, and may support adherence to the overall treatment plan. This supportive relief is particularly relevant in situations involving recurrent or episodic manifestations of high glucose.

Regulatory References

1. European Medicines Agency overview of Lantus

The eligibility for using Lantus (insulin glargine) is strictly defined by regulatory documents based on patient age, underlying conditions, and physiological state.

Lantus is approved for use in adults with Type 1 or Type 2 diabetes. It is approved for pediatric patients (children and adolescents) with Type 1 diabetes aged 6 years and older. Safety and efficacy have not been established in children younger than 6 years of age.

Use in certain populations requires special caution and may necessitate a dosage reduction due to the risk of diminished insulin metabolism. These groups include patients with renal impairment (kidney disease) or hepatic impairment (liver disease).

Regarding pregnancy, Lantus can be used when clinically indicated, and women who are breastfeeding may also use the medicine, though diet and insulin dose adjustments may be needed. Lantus is not recommended for the treatment of diabetic ketoacidosis (DKA).

The documented interaction profile for Insulin Glargine is dominated by pharmacodynamic (PD) interactions with substances that alter blood glucose concentrations. These official interaction patterns are classified based on the potential to either enhance or decrease the blood-glucose-lowering effect of the medicine.

Medicinal Products that Enhance the Glucose-Lowering Effect

Co-administration with certain medicinal products may increase the susceptibility to hypoglycemia. These agents include oral antidiabetic medicines, Angiotensin Converting Enzyme (ACE) inhibitors, Monoamine Oxidase Inhibitors (MAOIs), salicylates, fibrates, and sulfonamide antibiotics.

Medicinal Products that Decrease the Glucose-Lowering Effect

Other agents are officially documented to counteract the intended effect, raising the risk of hyperglycemia. This group includes corticosteroids, diuretics, thyroid hormones, estrogens and progestogens, danazol, and sympathomimetic agents.

Other Interaction-Related Outcomes

Certain substances, such as beta-blockers, clonidine, and reserpine, may officially mask the physical signs and symptoms of hypoglycemia. Furthermore, alcohol consumption is explicitly noted to potentially potentiate the glucose-lowering effect. Regulatory information also specifies that the co-administration of insulin with thiazolidinediones, like pioglitazone, is associated with a risk of fluid retention and heart failure. No mandatory timing rules are documented for separating the administration of Insulin Glargine from other medicines, and no specific CYP-enzyme-mediated pharmacokinetic interactions are described in regulatory labeling.

Insulin glargine, an insulin analog, functions as an agonist at the transmembrane Insulin Receptor (IR), a disulfide-linked alpha2beta2 heterotetramer primarily expressed on target cells in the liver, skeletal muscle, and adipose tissue. Upon binding to the extracellular alpha subunits, glargine initiates a conformational change that activates the intrinsic tyrosine kinase domain of the intracellular beta subunits.

This activation leads to autophosphorylation of the beta subunits and subsequent phosphorylation of key intracellular substrates, including Insulin Receptor Substrates (IRS proteins). Tyrosine phosphorylation of IRS proteins recruits the Phosphatidylinositol 3-kinase (PI3K) enzyme, which catalyzes the production of phosphatidylinositol (3,4,5)-trisphosphate ( PIP3). PIP3 then activates Protein Kinase B (Akt).

The downstream Akt cascade mediates the principal metabolic effects: it stimulates the translocation of Glucose Transporter 4 (GLUT4) vesicles from the cytoplasm to the plasma membrane in muscle and adipocytes, facilitating glucose influx. Concurrently, Akt inhibits glycogen synthase kinase-3 ( GSK-3beta), thereby modulating glycogen synthase to promote glycogen storage, and suppresses hepatic glucose output by inhibiting gluconeogenic enzymes. These intracellular events culminate in systemic modulation of glucose and lipid metabolism.

The pharmacodynamic profile is extended by the formation of microprecipitates at the subcutaneous injection site, which slowly release the active compound, resulting in a relatively constant concentration profile over 24 hours.

Administration Overview

Lantus is a long-acting insulin glargine solution intended for subcutaneous administration. It is typically administered once daily at the same time each day to maintain a steady basal insulin level. The medication is injected into the subcutaneous tissue of the abdominal wall, the thigh, or the upper arm.

Injection Site Rotation

To reduce the risk of localized skin complications, such as lipodystrophy or localized cutaneous amyloidosis, it is important to rotate injection sites within the chosen area. Each subsequent injection should be administered at a different spot from the previous one. Rotating sites helps ensure consistent absorption of the insulin and maintains the health of the underlying tissue.

Preparation and Handling

Before administration, the solution should be inspected visually. It must be clear and colorless, with no visible particles. Lantus should not be mixed or diluted with any other insulin or solution, as this can change its profile of action or cause the insulin to precipitate.

Usage Considerations

The timing of the daily dose should remain consistent to achieve optimal metabolic control. Proper technique involves ensuring the needle is inserted correctly into the subcutaneous layer and not into the muscle or a vein. Consistent adherence to the established routine is a primary factor in the effective management of blood glucose levels.

Research Evidence / Overview of Studies for Lantus (Insulin Glargine)

The research available for Lantus, which contains the active ingredient insulin glargine, comes primarily from Randomized Controlled Trials (RCTs) and long-term observational studies. These studies were conducted to examine its profile as a basal insulin source in managing high blood sugar levels. Findings describe patterns observed in the studies regarding the continuous supply of background insulin and measured changes in certain biomarkers.

Evidence for Use in Type 1 Diabetes Mellitus (T1DM)

For adults with Type 1 diabetes, comparative RCTs examined changes in biomarkers like HbA1c and Fasting Plasma Glucose ( FPG) levels. Trials reported measurements of these biomarkers when comparing Lantus to older basal insulins, such as NPH. Research highlights patterns in the observed frequency of nocturnal hypoglycemia in the Lantus groups compared to NPH insulin groups. While short-term studies up to 52 weeks are available in the evidence base, long-term comparative evidence against all of the newest basal insulin analogues remains uncertain.

Evidence for Use in Type 2 Diabetes Mellitus (T2DM)

The evidence base for Type 2 diabetes includes standard RCTs and a major, dedicated long-term cardiovascular outcome trial known as ORIGIN. Studies explored the use of Lantus, often combined with oral medications, and monitored changes in HbA1c and FPG. Findings reported measurements of blood sugar control and described patterns in nocturnal hypoglycemia frequency when comparing Lantus to NPH insulin.

Long-Term Follow-up and Specific Populations

The ORIGIN trial tracked T2DM patients with high cardiovascular risk for a median of 6.2 years to observe long-term cardiovascular outcomes. The data reported that the incidence of major cardiovascular events was comparable to the standard care group in the study population. Dedicated studies explored the use in pediatric patients (aged 6 years) with T1DM. However, data for children younger than six years of age remain insufficient in the core regulatory evidence. Long-term effects are not fully established for all outcomes in all patient groups beyond the duration of the longest trials, and comparative evidence is lacking for direct comparisons against all newer basal insulin analogues.

Key Studies & References

1. Insulin glargine versus NPH insulin in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

Common questions about Лантус (FAQ)

Q: What is Лантус (insulin glargine)?

A: Лантус is a long-acting form of human insulin known as insulin glargine. It is indicated to help manage high blood sugar levels in adults and children with type 1 diabetes and in adults with type 2 diabetes.

Q: How does Лантус work?

A: Insulin glargine is designed to release insulin slowly and steadily over 24 hours. This continuous action helps to provide a background or basal level of insulin throughout the day and night.

Q: What is the most common side effect of Лантус?

A: The most common side effect reported with any insulin, including Лантус, is hypoglycemia, or low blood sugar. Symptoms may include dizziness, sweating, confusion, and headache.

Q: Is Лантус the same as other insulins?

A: Лантус is an insulin analogue that is different from short-acting or intermediate-acting insulins. Its key characteristic is its prolonged duration of action, which offers 24-hour basal coverage with a single daily administration.

Storage and Disposal Conditions for Lantus (Insulin Glargine)

Lantus must be stored and handled according to strict regulatory requirements to maintain its stability.

Required Storage Conditions

Opened pens or cartridges must not be refrigerated. All forms of Lantus must be stored out of the sight and reach of children. Used needles and the disposable pen must be placed into an FDA-cleared sharps disposal container immediately after use. Disposal of unused product and the sharps container must follow local community medical waste guidelines.